Detailed Mechanism Funding and Narrative

Years of mechanism: 2014 2015 2016 2017 2018

Details for Mechanism ID: 17747
Country/Region: Nigeria
Year: 2016
Main Partner: Henry M. Jackson Foundation for the Advancement of Military Medicine
Main Partner Program: NA
Organizational Type: Private Contractor
Funding Agency: USDOD
Total Funding: $4,692,362 Additional Pipeline Funding: $3,120,890

NOTE: PEPFAR no longer creates activity narratives for each mechanism. In their place, PEPFAR has begun releasing mechanism specific targets that reveal the achievements and programs that are expected of the funding. If available for this mechanism, these targets are presented below.

Mechanism Allocation by Budget Code for Selected Year
Care: Adult Care and Support (HBHC) $1,239,525
Care: Orphans and Vulnerable Children (HKID) $0
Care: TB/HIV (HVTB) $195,919
Care: Pediatric Care and Support (PDCS) $325,743
Laboratory Infrastructure (HLAB) $0
Strategic Information (HVSI) $650,000
Health Systems Strengthening (OHSS) $0
Biomedical Prevention: Blood Safety (HMBL) $0
Biomedical Prevention: Injection Safety (HMIN) $0
Prevention: HIV Testing and Counseling (HVCT) $0
Sexual Prevention: Other Sexual Prevention (HVOP) $636,711
Biomedical Prevention: Prevention of Mother to Child Transmission (MTCT) $1,252,242
Treatment: Adult Treatment (HTXS) $392,222
Treatment: Pediatric Treatment (PDTX) $0
Mechanism Target Information

Since COP2014, PEPFAR no longer produces narratives for every mechanism it funds. However, PEPFAR has now included performance targets or indicator information for each mechanism based on the Monitoring, Evaluation, and Reporting (MER) system. The MER guidance is available on PEPFAR's website https://www.pepfar.gov/reports/guidance/. Note that COP years 2014-2015 were under a previous version of the MER system and the indicators and definitions may have changed as of the new 2.0 guidance.

MER Indicator MER description Target Fiscal Year Target
GEND_GBV_DSD By PEP service provision (related to sexual violence services provided) 2017 288
GEND_GBV_DSD By type of service: Physical and/or Emotional Violence (Other Post-GBV Care) 2017 93
GEND_GBV_DSD By type of service: Sexual Violence (Post-Rape Care) 2017 320
GEND_GBV_DSD Number of people receiving post-GBV care 2017 413
HTC_TST_DSD Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: 15+ Female 2017 85,081
HTC_TST_DSD Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: 15+ Male 2017 31,807
HTC_TST_DSD Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: <15 Female 2017 714
HTC_TST_DSD Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: <15 Male 2017 633
HTC_TST_DSD Number of individuals who received T&C services for HIV and received their test results during the past 12 months 2017 118,235
HTC_TST_DSD Service Delivery Point (Community): Mobile testing 2017 29,559
HTC_TST_DSD Service Delivery Point (Facility): Inpatient 2017 184
HTC_TST_DSD Service Delivery Point (Facility): Other PITC 2017 10,080
HTC_TST_DSD Service Delivery Point (Facility): Outpatient 2017 26,750
HTC_TST_DSD Service Delivery Point (Facility): Pediatric 2017 1,347
HTC_TST_DSD Service Delivery Point (Facility): PMTCT 2017 49,214
HTC_TST_DSD Service Delivery Point (Facility): TB Clinics 2017 1,101
HTC_TST_DSD Service Delivery Point (Facility): VCT 2017 29,559
HTC_TST_DSD Sum of Aggregated Age/Sex 15+ 2017 116,888
HTC_TST_DSD Sum of Aggregated Age/Sex <15 2017 1,347
HTC_TST_DSD Sum of Aggregated Age/Sex disaggregates 2017 118,235
HTC_TST_DSD Test Result by Aggregated Age and Sex: Positive 15+ Female 2017 3,122
HTC_TST_DSD Test Result by Aggregated Age and Sex: Positive 15+ Male 2017 1,206
HTC_TST_DSD Test Result by Aggregated Age and Sex: Positive <15 Female 2017 140
HTC_TST_DSD Test Result by Aggregated Age and Sex: Positive <15 Male 2017 112
KP_PREV_DSD By key population type: Female sex workers (FSW) (Denominator: Total estimated number of key population in the catchment area) 2017 5,672
KP_PREV_DSD By key population type: Female sex workers (FSW) (Numerator: Number of key populations reached with individual and/or small group level HIV preventive interventions that are based on evidence and/or meet the minimum standards required) 2017 4,821
KP_PREV_DSD By key population type: Females who inject drugs (Female PWID) (Denominator: Total estimated number of key population in the catchment area) 2017 13
KP_PREV_DSD By key population type: Females who inject drugs (Female PWID) (Numerator: Number of key populations reached with individual and/or small group level HIV preventive interventions that are based on evidence and/or meet the minimum standards required) 2017 11
KP_PREV_DSD By key population type: Males who inject drugs (Male PWID) (Denominator: Total estimated number of key population in the catchment area) 2017 189
KP_PREV_DSD By key population type: Males who inject drugs (Male PWID) (Numerator: Number of key populations reached with individual and/or small group level HIV preventive interventions that are based on evidence and/or meet the minimum standards required) 2017 161
KP_PREV_DSD By key population type: Men who have sex with men who are NOT sex workers (Denominator: Total estimated number of key population in the catchment area) 2017 3,612
KP_PREV_DSD By key population type: Men who have sex with men who are NOT sex workers (Numerator: Number of key populations reached with individual and/or small group level HIV preventive interventions that are based on evidence and/or meet the minimum standards required) 2017 3,070
KP_PREV_DSD Number of key populations reached with individual and/or small group level HIV preventive interventions that are based on evidence and/or meet the minimum standards required 2017 8,063
KP_PREV_DSD Total estimated number of key population in the catchment area 2017 9,486
LAB_PT_DSD CD4: Number of laboratories that achieve acceptable successful passing criteria in this PT program 2017 15
LAB_PT_DSD CD4: Number of laboratories that participate in this PT program 2017 18
LAB_PT_DSD CD4: Number of laboratories that perform this testing 2017 18
LAB_PT_DSD Early infant diagnostics: Number of laboratories that achieve acceptable successful passing criteria in this PT program 2017 2
LAB_PT_DSD Early infant diagnostics: Number of laboratories that participate in this PT program 2017 2
LAB_PT_DSD Early infant diagnostics: Number of laboratories that perform this testing 2017 2
LAB_PT_DSD HIV serologic/diagnostic testing: Number of laboratories that achieve acceptable successful passing criteria in this PT program 2017 23
LAB_PT_DSD HIV serologic/diagnostic testing: Number of laboratories that participate in this PT program 2017 23
LAB_PT_DSD HIV serologic/diagnostic testing: Number of laboratories that perform this testing 2017 25
LAB_PT_DSD HIV viral load: Number of laboratories that achieve acceptable successful passing criteria in this PT program 2017 2
LAB_PT_DSD HIV viral load: Number of laboratories that participate in this PT program 2017 2
LAB_PT_DSD HIV viral load: Number of laboratories that perform this testing 2017 2
LAB_PT_DSD TB diagnostics (AFB microscopy): Number of laboratories that achieve acceptable successful passing criteria in this PT program 2017 19
LAB_PT_DSD TB diagnostics (AFB microscopy): Number of laboratories that participate in this PT program 2017 22
LAB_PT_DSD TB diagnostics (AFB microscopy): Number of laboratories that perform this testing 2017 22
LAB_PT_DSD TB diagnostics (Xpert MTB/RIF): Number of laboratories that achieve acceptable successful passing criteria in this PT program 2017 9
LAB_PT_DSD TB diagnostics (Xpert MTB/RIF): Number of laboratories that participate in this PT program 2017 11
LAB_PT_DSD TB diagnostics (Xpert MTB/RIF): Number of laboratories that perform this testing 2017 11
PMTCT_ART_DSD Already on ART at beginning of current pregnancy 2017 3,179
PMTCT_ART_DSD New on ART 2017 865
PMTCT_ART_DSD Number of pregnant women with known HIV status (includes women who were tested for HIV and received their results) 2017 49,214
PMTCT_EID_DSD By infants who received a virologic test within 2 months of birth 2017 3,033
PMTCT_EID_DSD By infants who received their first virologic HIV test between 2 and 12 months of age 2017 1,011
PMTCT_EID_DSD Number of infants with a positive virological test result within 12 months of birth 2017 8
PMTCT_EID_DSD Number of infants with a positive virological test result within 2 months of birth 2017 23
PMTCT_EID_DSD Sum of Infant Age disaggregates 2017 4,044
PMTCT_STAT_DSD By: Known positives at entry 2017 2,481
PMTCT_STAT_DSD By: Number of new positives identified 2017 1,776
PMTCT_STAT_DSD Number of new ANC and L&D clients 2017 51,804
PMTCT_STAT_DSD Number of pregnant women with known HIV status (includes women who were tested for HIV and received their results) 2017 49,214
PMTCT_STAT_DSD Sum of Positives Status disaggregates 2017 4,257
TB_ART_DSD Aggregated Age/Sex: Female 15+ (Numerator: The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period) 2017 12
TB_ART_DSD Aggregated Age/Sex: Female <15 (Numerator: The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period) 2017 1
TB_ART_DSD Aggregated Age/Sex: Male 15+ (Numerator: The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period) 2017 11
TB_ART_DSD Aggregated Age/Sex: Male <15 (Numerator: The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period) 2017 1
TB_ART_DSD The number of registered new and relapse TB cases with documented HIV-positive status during TB treatment during the reporting period 2017 28
TB_ART_DSD The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period 2017 25
TB_SCREENDX_DSD Screen Result: Screened Positive for TB 2017 633
TB_SCREENDX_DSD Screened for TB by Age/Sex: 15+ Female 2017 17,517
TB_SCREENDX_DSD Screened for TB by Age/Sex: 15+ Male 2017 8,923
TB_SCREENDX_DSD Screened for TB by Age/Sex:<15 Female 2017 511
TB_SCREENDX_DSD Screened for TB by Age/Sex:<15 Male 2017 560
TB_SCREENDX_DSD The number of PLHIV who were screened for TB symptoms at the last clinical visit at a HIV facility during the reporting period 2017 27,511
TB_SCREENDX_DSD [Sub-Disagg of Screen Result] Specimen Sent: Specimen sent for bacteriologic diagnosis of active TB 2017 569
TB_SCREENDX_DSD [Sub-Disagg of Specimen Sent] Diagnostic Test: Xpert MTB/RIF assay 2017 513
TB_STAT_DSD Aggregated Age/Sex: Female 15+ (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period) 2017 57
TB_STAT_DSD Aggregated Age/Sex: Female <15 (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period) 2017 3
TB_STAT_DSD Aggregated Age/Sex: Male 15+ (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period) 2017 85
TB_STAT_DSD Aggregated Age/Sex: Male <15 (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period) 2017 4
TB_STAT_DSD Number of registered new and relapsed TB cases with documented HIV status, during the reporting period 2017 149
TB_STAT_DSD Total number of registered new and relapsed TB cases, during the reporting period 2017 165
TX_CURR_DSD Aggregated Age/Sex: 15+ Female 2017 17,862
TX_CURR_DSD Aggregated Age/Sex: 15+ Male 2017 9,099
TX_CURR_DSD Aggregated Age/Sex: <15 Female 2017 262
TX_CURR_DSD Aggregated Age/Sex: <15 Male 2017 288
TX_CURR_DSD Number of adults and children receiving antiretroviral therapy (ART) 2017 27,511
TX_CURR_DSD Sum of Aggregated Age/Sex 15+ 2017 26,961
TX_CURR_DSD Sum of Aggregated Age/Sex <15 2017 550
TX_CURR_DSD Sum of Aggregated Age/Sex disaggregates 2017 27,511
TX_NEW_DSD Aggregated Grouping by Age/Sex: 15+ Female 2017 2,143
TX_NEW_DSD Aggregated Grouping by Age/Sex: 15+ Male 2017 1,900
TX_NEW_DSD Aggregated Grouping by Age/Sex: <15 Female 2017 44
TX_NEW_DSD Aggregated Grouping by Age/Sex: <15 Male 2017 39
TX_NEW_DSD Number of adults and children newly enrolled on antiretroviral therapy (ART) 2017 4,126
TX_NEW_DSD Sum of Aggregated Age/Sex disaggregates 2017 4,126
TX_PVLS_DSD Denominator Aggregated Age/Sex: 15+ Female 2017 17,517
TX_PVLS_DSD Denominator Aggregated Age/Sex: 15+ Male 2017 8,923
TX_PVLS_DSD Denominator Aggregated Age/Sex: <15 Female 2017 511
TX_PVLS_DSD Denominator Aggregated Age/Sex: <15 Male 2017 560
TX_PVLS_DSD Denominator: Indication: Routine 2017 22,009
TX_PVLS_DSD Denominator: Indication: Targeted 2017 5,502
TX_PVLS_DSD Number of adult and pediatric ART patients with a viral load result documented in the patient medical record and /or laboratory records in the past 12 months 2017 27,511
TX_PVLS_DSD Number of adults and pediatric patients on ART with suppressed viral load results (<1,000 copies/ml) documented in the medical records and /or supporting laboratory results within the past 12 months 2017 24,760
TX_PVLS_DSD Numerator Aggregated Age/Sex: 15+ Female 2017 15,765
TX_PVLS_DSD Numerator Aggregated Age/Sex: 15+ Male 2017 8,031
TX_PVLS_DSD Numerator Aggregated Age/Sex: <15 Female 2017 460
TX_PVLS_DSD Numerator Aggregated Age/Sex: <15 Male 2017 504
TX_PVLS_DSD Numerator: Indication: Routine 2017 19,808
TX_PVLS_DSD Numerator: Indication: Targeted 2017 4,952
TX_RET_DSD Aggregated Age/Sex: 15+ Female (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up) 2017 5,652
TX_RET_DSD Aggregated Age/Sex: 15+ Female (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART) 2017 4,521
TX_RET_DSD Aggregated Age/Sex: 15+ Male (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up) 2017 2,878
TX_RET_DSD Aggregated Age/Sex: 15+ Male (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART) 2017 2,303
TX_RET_DSD Aggregated Age/Sex: <15 Female (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up) 2017 165
TX_RET_DSD Aggregated Age/Sex: <15 Female (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART) 2017 132
TX_RET_DSD Aggregated Age/Sex: <15 Male (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up) 2017 181
TX_RET_DSD Aggregated Age/Sex: <15 Male (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART) 2017 145
TX_RET_DSD Number of adults and children who are still alive and on treatment at 12 months after initiating ART 2017 7,101
TX_RET_DSD Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up 2017 8,876
Cross Cutting Budget Categories and Known Amounts Total: $1,680,000
Human Resources for Health $1,000,000
Key Populations: MSM and TG $100,000
Implementation of core HIV prevention interventions for MSM/TG that are consistent with the current PEPFAR technical guidance
Collection and use of strategic information
Conducting epidemiologic, social science, and operational research among MSM/TG and their sex partners
Monitoring and evaluation of MSM/TG programs
Training of health workers and community outreach workers
Key Populations: FSW $150,000
Conducting epidemiologic, social science, and operational research among SWs, their partners, and clients
Implementation of core HIV prevention interventions for SWs consistent with PEPFAR guidance on sexual prevention
Collection and use of strategic information on SWs and clients
Training of health workers and community outreach workers
Gender: Gender Based Violence (GBV) $100,000
GBV Prevention
Collection and Use of Gender-related Strategic Information
Implementation
Capacity building
Monitoring and Evaluation
Operation Research
Gender: Gender Equality $50,000
Equity in HIV prevention, care, treatment and support
Collection and Use of Gender-related Strategic Information
Implementation
Capacity building
Monitoring and Evaluation
Operation Research
Changing harmful gender norms and promoting positive gender norms
Collection and Use of Gender-related Strategic Information
Implementation
Capacity building
Monitoring and Evaluation
Promoting gender-related policies and laws that increase legal protection
Collection and Use of Gender-related Strategic Information
Implementation
Capacity building
Monitoring and Evaluation
Increase gender-equitable access to income and productive resources, including education
Collection and Use of Gender-related Strategic Information
Implementation
Capacity building
Monitoring and Evaluation
Operation Research
Condoms: Commodities $180,000
Condoms: Policy, Tools, and Services $100,000